Arbutus Biopharma
ABUS
ABUS
51 hedge funds and large institutions have $173M invested in Arbutus Biopharma in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
4% less funds holding
Funds holding: 53 → 51 (-2)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
17% less capital invested
Capital invested by funds: $207M → $173M (-$34.3M)
Holders
51
Holding in Top 10
2
Calls
$149K
Puts
$5K
Top Buyers
| 1 | +$3.74M | |
| 2 | +$1.42M | |
| 3 | +$1.22M | |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.11M |
| 5 |
Morgan Stanley
New York
|
+$1.05M |
Top Sellers
| 1 | -$2.77M | |
| 2 | -$1.39M | |
| 3 | -$1.09M | |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$775K |
| 5 |
RI
RTW Investments
New York
|
-$579K |